{"id":27254,"date":"2024-04-24T12:46:59","date_gmt":"2024-04-24T10:46:59","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=27254"},"modified":"2024-04-26T10:29:40","modified_gmt":"2024-04-26T08:29:40","slug":"impilo-and-kkr-has-entered-into-a-strategic-partnership-together-with-management-in-rare-disease-platform-immedica-pharma","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/impilo-and-kkr-has-entered-into-a-strategic-partnership-together-with-management-in-rare-disease-platform-immedica-pharma\/","title":{"rendered":"Impilo and KKR has entered into a strategic partnership together with management in Immedica Pharma"},"content":{"rendered":"<p class=\"preamble\">Impilo has entered into an agreement to divest (alongside the minority shareholders) its majority stake in Immedica Pharma, a pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care products, to KKR, a leading global investment firm.<\/p>\n<p>In the transaction, Impilo will reinvest to become an equal owner alongside KKR, and the parties will work together with Immedica\u2019s management team to support the Immedica\u2019s continued growth. The transaction is subject to customary regulatory and closing conditions.<\/p>\n<p>Immedica Pharma was established in 2018 by Impilo and an experienced management team. The business has built up a portfolio and pipeline of drugs, primarily within hematology and oncology as well as genetic and metabolic diseases for rare conditions with high unmet medical need, and has quickly expanded into an emerging leader in the European rare disease space, with revenues of EUR 100m and annual growth of more than 50%.<\/p>\n<p>Mannheimer Swartling advised Impilo in the transaction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Impilo has entered into an agreement to divest (alongside the minority shareholders) its majority stake in Immedica Pharma, a pharmaceutical company focused on the commercialization\u2026<\/p>\n","protected":false},"author":16,"featured_media":27251,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-27254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-assignment","business-group-banking-and-finance","business-group-mergers-and-acquisitions","business-group-private-equity"],"acf":[],"lang":"en","translations":{"en":27254,"sv":27249},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27254"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=27254"}],"version-history":[{"count":3,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27254\/revisions"}],"predecessor-version":[{"id":27264,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27254\/revisions\/27264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/27251"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=27254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=27254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=27254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}